10/06/2022
Medical trial shows rare result as cancer vanishes in all patients:
In a medical trial, 12 patients in the United States were completely cured of re**al cancer without requiring any surgery or chemotherapy.
The study was done by doctors from the Memorial Sloan Kettering Cancer Centre in New York, and its results have been published in the New England Journal of Medicine.
The trial used a monoclonal antibody called dostarlimab every three weeks for six months for the treatment of a particular kind of stage two or three re**al cancer.
All patients in the study were in similar stages of their cancer. It was locally advanced in the re**um but had not spread to other organs.
Findings of the study:
Immunotherapy: The trial showed that immunotherapy alone without any chemotherapy, radiotherapy, or surgery that have been staples of cancer treatment could completely cure the patients with a particular kind of re**al cancer called ‘mismatch repair deficient’
Protein regulation: The therapy in the trial used PD1 blockades, allowing T cells to kill cancer cells. PD1 is a type of protein that regulates certain functions of the immune system, including by suppressing T cell activity, and PD1 blockade therapy looks to release the T cells from this suppression.
No recurrence: No cases of progression or recurrence had been reported during the follow-up.
Early cure: The response too was rapid, with symptoms resolving in 81% of the patients within nine weeks of starting the therapy.
Complete remission: The patients involved in the cancer drug trial had undergone treatments such as radiation, chemotherapy, and invasive surgery that could result in urinary, bowel, and even sexual dysfunction.
The findings of the latest cancer drug trial have shocked the medical experts who pointed out that the complete remission in every single patient is unheard off.
About Mismatch repair deficient cancer :
Site of occurrence: ‘Mismatch repair deficient’ cancer is most common among colore**al, gastrointestinal, and endometrial cancers.
Genetics: The anomalies in the DNA result in cancerous growths in patients with mismatch repair deficient cancers. Patients suffering from this condition lack the genes to correct typos in the DNA that occur naturally while cells make copies.
New conclusions in the trial :
No surgery needed: Though PD1 therapy was already in use, but earlier it was used post-surgery, but the study has shown that a surgery may not be required.
Extensive application: Till now, the PD1 therapy was usually used for cancers that have metastasized (spread to locations other than where the cancer formed). But it is now recommended for all mismatch repair deficient cancers.
Efficiency: PD1 therapy result in quicker improvement and lesser toxicity as compared to traditional chemo and radiotherapy.
Minimizing treatment: Eliminating other treatments can improve a patient’s quality of life by preserving fertility, sexual health, and bladder and bowel functions.
About Monoclonal antibodies :
Monoclonal antibodies like dostarlimab are laboratory-made antibodies design to fight specific illnesses.
Dostarlimab is specifically designed to block a particular protein involved in cancer cells called PD-1. According to the experts, ‘Dostarlimab’ is a drug with laboratory-produced molecules acting as a substitute for antibodies in the human body.
Scope of treatment in India :
India also has a couple of PD1 blockades available, although not the one used for the study in US trial.
Statistics: In India, cancer mortality has doubled from 1990 to 2016. India’s cancer incidence was estimated at 1.15 million new patients in 2018 and is predicted to almost double as a result of demographic changes alone by 2040.
Inhibitory costs: High cost is believed to be a major hurdle in PD1 blockades therapy in India. A genetic test may also cost up to Rs 30,000 and the patients in India cannot afford all this.
An immunotherapy treatment can cost around Rs 4 lakh per month, with patients needing the treatment for six months to a year.
Limitations: Doctors are also apprehensive of immunotherapy approach as according to them patients can be well managed with chemotherapy and radiotherapy as well.
Restricted surgery: Also, the claim of the trial that a patient may not need surgery is rebutted by the fact that around 10 to 15% of cancer patients actually do not need surgeries.
Health Insurance: Only those persons can afford treatment who can bank on schemes such as Central Govt Health Scheme (CGHS) for sponsoring their treatment or receive free doses from the companies as part of their assistance programme. In 1954, the Central Govt Health Scheme was launched for the current as well as former employees of the Central Government of India.
Finite research: The precision medicine, such as using particular immunotherapy drugs for particular types of cancers, is still at a nascent stage in India and it would take at least ten years for it to become commonplace.
Conclusion :
The cancer researchers who reviewed the drug informed that the treatment on drugs looks promising; however, a large-scale trial is required. If proven effective on a larger group of patients, the discovery of Dostarlimab can revolutionise cancer care and stop the exploitation of millions of vulnerable patients by quacks selling unproven therapies to cure and control cancer.
The future of cancer treatment is molecular oncology thus holds assuring results as a mutation in one gene may be given a particular medicine and mutation found in another gene may be given another medicine.
